|
|
Vaccine Detail
|
PA-1-STK Ovarian Carcinoma Vaccine |
| Vaccine Information |
- Vaccine Name: PA-1-STK Ovarian Carcinoma Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007135
- Type: Multipeptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- PAGR1
gene engineering:
- Preparation: An ovarian carcinoma cell line, PA-1, has been transduced to express the Herpes Simplex Virus Thymidine Kinase, PA-1-STK (Freeman et al., 1995).
- Description: This is for Ovarian Cancer (NCT00006216).A cell-based cancer vaccine with potential antineoplastic activity. PA-1-STK ovarian carcinoma vaccine is produced by transducing the ovarian cancer cell line, PA-1, with the herpes simplex thymidine kinase (HSV-tk) gene, resulting in a cell line, PA-1-STK, that permanently expresses the HSV tk gene. Upon transfection into malignant cells, this vaccine is capable of sensitizing tumor cells in response to an antiviral drug such as ganciclovir, which is readily phosphorylated by the TK enzyme to its active form. Administration of ganciclovir following PA-1 STK transfection results in enhanced cytotoxicity of the transfected tumor cells. Additionally, adjacent non-transfected cells are also killed by the activated antiviral drug, a phenomenon referred to as the bystander effect that occurs with this type of suicide-gene transfer technique (Freeman et al., 1995; NCIT_C2428).
|
| Host Response |
|
|
| References |
Freeman et al., 1995: Freeman SM, McCune C, Robinson W, Abboud CN, Abraham GN, Angel C, Marrogi A. The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. Human gene therapy. 1995; 6(7); 927-939. [PubMed: 7578411].
NCIT_C2428: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2428]
NCT00006216: [https://clinicaltrials.gov/ct2/show/NCT00006216]
|
|
